In the last trading session, 6.87 million shares of the Bluebird bio Inc (NASDAQ:BLUE) were traded, and its beta was 0.75. Most recently the company’s share price was $0.52, and it changed around -$0.05 or -8.67% from the last close, which brings the market valuation of the company to $100.95M. BLUE currently trades at a discount to its 52-week high of $5.53, offering almost -963.46% off that amount. The share price’s 52-week low was $0.45, which indicates that the current value has risen by an impressive 13.46% since then. We note from Bluebird bio Inc’s average daily trading volume that its 10-day average is 8.25 million shares, with the 3-month average coming to 7.59 million.
Bluebird bio Inc stock received a consensus recommendation rating of Buy, based on a mean score of 2.80. If we narrow it down even further, the data shows that 1 out of 18 analysts rate the stock as a Sell; another 5 rate it as Overweight. Among the rest, 5 recommended BLUE as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight. Bluebird bio Inc is expected to report earnings per share of -0.36 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Bluebird bio Inc (NASDAQ:BLUE) trade information
Instantly BLUE has showed a red trend with a performance of -8.67% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.5750 on recent trading dayincreased the stock’s daily price by 9.57%. The company’s shares are currently down -62.28% year-to-date, but still up 0.21% over the last five days. On the other hand, Bluebird bio Inc (NASDAQ:BLUE) is -1.57% down in the 30-day period. We can see from the shorts that 48.4 million shares have been sold at a short interest cover period of 4.75 day(s).
The consensus price target as assigned by Wall Street analysts is $12.5, which translates to bulls needing to increase their stock price by 95.84% from its current value. Analyst projections state that BLUE is forecast to be at a low of $5 and a high of $25.
Bluebird bio Inc (BLUE) estimates and forecasts
Bluebird bio Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -55.12 percent over the past six months and at a 26.42% annual growth rate that is well above the industry average of 17.60%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 45.50% in revenue this quarter, and will report an increase of 62.80% in the next quarter. The year-over-year growth rate is expected to be 193.40%, up from the previous year.
Consensus estimates provided by 9 financial analysts predict the company will bring in an average of 18.05M in revenue for the current quarter. 8 analysts expect Bluebird bio Inc to make 27.91M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 256.30%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 28.98%. Bluebird bio Inc earnings are expected to increase by 20.24% in 2024, but the outlook is positive 45.80% per year for the next five years.
BLUE Dividends
Bluebird bio Inc’s next quarterly earnings report is expected to be released in November.
Bluebird bio Inc (NASDAQ:BLUE)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.44% of Bluebird bio Inc shares, and 43.44% of them are in the hands of institutional investors. The stock currently has a share float of 43.63%. Bluebird bio Inc stock is held by 205.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 14.1544% of the shares, which is about 15.44 million shares worth $15.2 million.
VANGUARD GROUP INC, with 9.4422% or 10.3 million shares worth $10.14 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
